Rare diseases
Investigational molecules
Locations
Weidkamp 1, 45355 Essen, Germany
Praxis am Markt in Essen, Germany specialises in clinical trials of conditions such as Obesity, Type 2 diabetes mellitus, Overweight, Arteriosclerosis, and other specialisations. This site conducts important research.
The program at Praxis am Markt investigates new treatments to reduce major cardiovascular events in patients with type 2 diabetes and atherosclerotic disease, while also exploring strategies for chronic kidney disease management.
By conducting these studies in Essen, Germany, the site contributes valuable data that can shape future cardiovascular guidelines.
Studies at this center focus on obesity, overweight, and type 2 diabetes, testing innovative agents that promote weight loss and improve metabolic health without requiring daily injections.
The work supports patients in Germany seeking sustainable solutions for metabolic disorders and informs clinical practice worldwide.
The site conducts research on chronic obstructive pulmonary disease (COPD), evaluating triple‑therapy inhalers to improve lung function and reduce severe cardiopulmonary events.
These investigations help refine COPD management strategies for patients across Europe, with Praxis am Markt providing a key recruitment hub.
Clinical trials currently enrolling participants at this site.
Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial
GermanyZenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
GermanyStudy on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)
GermanyPhase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity
GermanyStudy of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications
GermanyComparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before
GermanyEfficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes
GermanyA study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.
GermanyStudy of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease
GermanyEvaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk
GermanyStudy comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor
GermanyStudy on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes
GermanyMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
